ClinicalTrials.gg

Program

GS-4321

A development code.

Its studies are mostly in Hepatitis D, Chronic, led by Gilead Sciences.

Furthest: phase 2, since Jul 24, 20251 company-led study, 1 open or runningNext primary completion: Jan 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences11 open or runningphase 2since Jul 24, 2025Jul 24, 2025Jan 2030phase 2 · NCT07096193

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 24, 2025First study: phase 2 study in Hepatitis D, ChronicFirst studyNCT07096193 · 200 planned · United States, Bulgaria, Germany and more

Ahead

  1. Jan 2030Primary completion: phase 2 study in Hepatitis D, ChronicNCT07096193

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07096193Hepatitis D, Chronic · United States, Bulgaria, Germany and more2RecruitingJan 2030200

How it is read

Names in the registry

  • “GS-4321”, 2 entries

Codes read as this program: GS4321.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.